KROS (Keros Corp) Multiplikator Forward P/S

Lambang korporat lan logo Keros Therapeutics (KROS)

Keros Therapeutics (KROS) develops therapies for blood pathologies, leveraging its existing cash reserves. The forward P/S ratio helps assess the fairness of the market valuation relative to future sales, with the value 4.90 capturing this metric. The environmental profile is based on the regulated disposal of biohazardous waste. The scientific team is motivated by equity and the platform's potential in treating bone diseases.

Keros Therapeutics, Inc. - Multiplikator Forward P/S KROS (periode 04.07.2022 - 17.11.2026)

Ringkesan rincian data analitis Keros Therapeutics (KROS)

Analisis fundamental perusahaan:KROS (Keros Therapeutics Inc)
Produk asli Keros Corp

A qualitative asset valuation requires an analysis of the ratio between market value and expected revenue. This indicator measures the resilience of the price trend amid changing tax conditions by comparing supply and demand. By analyzing the forward P/S dynamics of Keros Therapeutics (KROS), an investor determines the balance between growth potential and correction risk. This is critical for Keros Therapeutics (KROS) during its expansion into the myelofibrosis and osteoporosis therapy segments.

Pesaing Keros Therapeutics

Rasio rega marang prakiraan pendapatan Vertex VRTX|ALNY (Alnylam Inc.) - Rega mangsa ngarep marang pendapatan|Insmed Incorporated - Multiplikator Forward P/S|Rega forward marang dodolan UTHR (United Therapeutics)|BMRN: Multiplikator Forward P/S|BridgeBio Pharma (BBIO) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan bgm.ltd|COGT: Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan xerispharma.com (XERS)|Multiplikator forward rega marang pendapatan Arcturus Therapeutics ARCT|Multiplikator Forward P/S ETON (etonpharma.com)|Multiplikator Forward P/S Kamada Ltd KMDA|Fulcrum Therapeutics, Inc. - Multiplikator Forward P/S|ABEO - Multiplikator Forward P/S|MREO: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Protalix BioTherapeutics, Inc. (PLX)|PLRX (Pliant Therapeutics, Inc.) - Multiplikator Forward P/S|Applied Therapeutics Inc. - Rega mangsa ngarep marang pendapatan|Rasio rega marang prakiraan pendapatan Rein Therapeutics Inc (RNTX)|Rasio rega marang pendapatan sing dikarepake GELS|Aytu BioPharma, Inc. - Multiplikator forward rega marang pendapatan|Chemomab Therapeutics (CMMB) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|SRx Health - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake Polyrizon Limited PLRZ|AEZS: Multiplikator Forward P/S|CYTH: Rasio rega marang pendapatan sing dikarepake|Multiplikator forward rega marang pendapatan INZY|RPHM: Rega forward marang dodolan|Multiplikator forward rega marang pendapatan CSCI (COSCIENS Biopharma)